QUICK ANSWER · AEO / GEO
A tuftsin-related heptapeptide with Russia-specific product history and limited human evidence; it is not FDA-approved.
ENTITY FACTS
What should readers identify first?
What remains unknown?
- replication in adequately powered blinded placebo-controlled trials
- long-term safety, immunogenicity and rare adverse events
- comparability of free peptide, diacetate, nasal drops and compounded formulations
- clinical significance of resting-state functional-connectivity changes
- efficacy for healthy cognition, sleep, depression or non-label uses
- current marketing-authorisation status in Thailand, the United States, European Union and United Kingdom
What limits these conclusions?
- The evidence base is geographically concentrated and many clinical articles are available primarily as short English abstracts. Comparator studies often lack placebo controls or enough methodological detail to assess bias. Registered-product claims come from a Russia-specific label and manufacturer materials. Formulation, route and sequence differences limit transfer to compounded or research products.
This overview does not replace the detailed adverse-event and product-specific risk discussion in the complete Thai profile or the original sources.
EVIDENCE BOUNDARY
What this overview does not establish
- An evidence grade does not rank this molecule against another treatment.
- A molecule name does not establish the identity, purity or regulatory status of a product.
- Animal, cell or biomarker findings do not automatically establish human clinical benefit.
- Approval in one country or indication does not transfer globally.
Where can I check the evidence?
Original sources from the same evidence record used by Compare. Read each source's population, methods, limitations and date; a citation is not product endorsement.
- https://www.lsgeotar.ru/drugs/selank-AGJ2/attachments
- https://selank.ru/files/o-selanke/instruktsiya/%D0%98%D0%BD%D1%81%D1%82%D1%80%D1%83%D0%BA%D1%86%D0%B8%D1%8F%20%D0%BF%D0%BE%20%D0%BC%D0%B5%D0%B4%D0%B8%D1%86%D0%B8%D0%BD%D1%81%D0%BA%D0%BE%D0%BC%D1%83%20%D0%BF%D1%80%D0%B8%D0%BC%D0%B5%D0%BD%D0%B5%D0%BD%D0%B8%D1%8E%20%D0%BB%D0%B5%D0%BA%D0%B0%D1%80%D1%81%D1%82%D0%B2%D0%B5%D0%BD%D0%BD%D0%BE%D0%B3%D0%BE%20%D0%BF%D1%80%D0%B5%D0%BF%D0%B0%D1%80%D0%B0%D1%82%D0%B0%20%D0%A1%D0%B5%D0%BB%D0%B0%D0%BD%D0%BA.pdf
- https://precision.fda.gov/ginas/app/ui/substances/d1af04cb-96d7-4c14-975d-4fff76d66847
- https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
- https://pubmed.ncbi.nlm.nih.gov/18454096/
- https://pubmed.ncbi.nlm.nih.gov/25176261/
- https://pubmed.ncbi.nlm.nih.gov/26356395/
- https://pubmed.ncbi.nlm.nih.gov/32342318/
- https://pubmed.ncbi.nlm.nih.gov/11550013/
- https://pubmed.ncbi.nlm.nih.gov/30255741/
- https://pubmed.ncbi.nlm.nih.gov/28280289/
- https://pubmed.ncbi.nlm.nih.gov/31625062/
- https://www.wada-ama.org/en/resources/world-anti-doping-program/prohibited-list
- https://products.mhra.gov.uk/
FAQ · ANSWER ENGINE
Frequently asked questions
What is Selank?
Selank is described pharmacologically as Synthetic tuftsin-related regulatory heptapeptide; registered nasal medicine in Russia. A tuftsin-related heptapeptide with Russia-specific product history and limited human evidence; it is not FDA-approved.
Does Selank have strong evidence?
PrimeCoreBio records Evidence Grade C. This grade describes evidence strength, not comparative effectiveness or suitability for an individual.
Is Selank approved everywhere?
No global conclusion should be inferred. PrimeCore Class A must be read with the exact product, country and indication on the source-rich profile.
Educational information only. This page does not provide diagnosis, treatment, prescribing, dosage, injection instructions or individual medical advice.